Renal Cell Cancer | Renal Cell Carcinoma CME Learning Center

Renal Cell Carcinoma
CME Learning Center

Liver Imaging with MRI CME Subtle cues derived from well-selected imaging sequences can distinguish benign and malignant masses and hepatic lesions from metastases.
Medscape Education Radiology, February 2012
Management of Treatment-Related Toxicities for Metastatic RCC CME/CE Dr. Hutson reviews management of treatment-related side effects related to kinase inhibitors to maximize efficacy and tolerability.
Medscape Education Oncology, December 2011
Tyrosine Kinase Inhibitor Therapy for Advanced Renal Cell Carcinoma: Current and Emerging Agents CME Dr. Motzer discusses the merits and toxicities of approved and investigational tyrosine kinase inhibitors used for metastatic renal cell carcinoma.
Medscape Education Oncology, November 2011
Nonaspirin NSAID Use Associated With Risk for Renal Cell Cancer CME Long-term use of nonaspirin anti-inflammatory drugs was linked to a risk for renal cell cancer, in an analysis of data from 2 prospective studies.
Medscape Education Clinical Briefs, September 2011
Selecting Targeted Therapies for Patients With Renal Cell Carcinoma CME Treatment choice for advanced RCC can be guided by the disease setting, histology, and patient characteristics, comorbidities, and preference, on the basis of available evidence.
JNCCN - Journal of the National Comprehensive Cancer Network, September 2011

Renal cell carcinoma is a heterogeneous group of sporadic or hereditary cancers that develop from kidney cells. Kidney cancer symptoms may include hematuria, back pain, and weight loss. Localized renal cell carcinoma is highly curable, and standard kidney cancer treatment is partial or radical nephrectomy. For those with metastatic renal cell carcinoma, the prognosis is poor, although newer, targeted agents show promise of extending survival.